Covered recipient · General Payments record
LISA KIM
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2021–2024
$1,714.35
- Reported across 63 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $422.51 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $139.63 | 5 |
| Exact Sciences Corporation | $86.33 | 4 |
| Acerta Pharma LLC | $45.38 | 2 |
| Merck Sharp & Dohme Corporation | $33.38 | 1 |
| DEXCOM, INC. | $30.45 | 1 |
| IRONWOOD PHARMACEUTICALS, INC | $24.55 | 1 |
| ABBVIE INC. | $24.34 | 1 |
| PFIZER INC. | $22.52 | 1 |
| Janssen Biotech, Inc. | $15.93 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.34 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104074298 | CMS |
| Amgen Inc. | $29.98 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111620232 | CMS |
| Amgen Inc. | $23.20 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111620234 | CMS |
| Amgen Inc. | $31.37 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111620236 | CMS |
| Amgen Inc. | $26.78 | 09/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111620238 | CMS |
| Amgen Inc. | $28.30 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111620240 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.77 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105582006 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.61 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105883685 | CMS |
| Dexcom, Inc. | $30.45 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153317082 | CMS |
| Exact Sciences Corporation | $19.11 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114735135 | CMS |
| Exact Sciences Corporation | $19.38 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114735140 | CMS |
| Exact Sciences Corporation | $23.56 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114735146 | CMS |
| Exact Sciences Corporation | $24.28 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114735152 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $24.55 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153769941 | CMS |
| Janssen Biotech, Inc. | $15.93 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078350865 | CMS |
| Merck Sharp & Dohme LLC | $33.38 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141789060 | CMS |
| PFIZER INC. | $22.52 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132017938 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.